Pazopanib induces dramatic but transient contraction of myeloid suppression compartment in favor of adaptive immunity
D. Rinchai, E. Verzoni, V. Huber, A. Cova, P. Squarcina, L. D. Cecco, F. d. Braud, R. Ratta, M. Dugo, L. Lalli, V. Vallacchi, M. Rodolfo, J. Roelands, C. Castelli, D. Chaussabel, , L. Rivoltini
This study shows pazopanib reduces myeloid suppression and boosts adaptive immunity in mRCC patients, with effects peaking at 3 months.
bioRxiv · May 1, 2020 · PreprintCancer Biology